Jonas Steglich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jonas Steglich has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Christine Mauz-Körholz
Department of Paediatric Oncology, Justus-Liebig-University Giessen, Giessen, Germany
3 shared publications - Dietrich Stoevesandt
Department of Radiology, University Hospital Halle, Halle/Saale, Germany
3 shared publications Dieter Körholz
Justus Liebig University G, Gießen, Germany
2 shared publications- Jamie E. Flerlage
Division of Pediatric Hematology/Oncology, Department of Pediatrics University of Rochester Medical Center Rochester New York USA
2 shared publications - Kara M. Kelly
Department of Pediatrics, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences , Buffalo, NY
2 shared publications Karin Dieckmann
Department of Radiation Oncology, Medical University of Vienna , Vienna
2 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5865-5873
EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma
Children and adolescents with early-stage nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) have a 5-year event-free survival (EFS) of about 77% after complete lymph node resection and around 89% with anthracycline-containing chemotherapy. We investigated whether patients with early-stage nLPHL can be successfully treated with surgical resection alone or with low-intensity, anthracycline-free CVP chemotherapy for those with unresectable nodal disease. EuroNet-PHL-LP1 was a prospective phase III trial enrolling patients under 18 years with stage IA/IIA nLPHL. Completely resected lymph nodes led to active surveillance. Patients with unresectable disease received three cycles of CVP (cyclophosphamide, vinblastine, prednisone). In CVP-cohort-1, treatment cessation required a negative 18F -FDG-PET. An amendment in 2014 omitted PET for end-of-treatment response; CT and/or MRI alone defined response in CVP-cohort-2. The primary endpoint was 5-year EFS, with death, relapse, second malignancy and PET-positivity counting as events; for CVP-cohort-2, progression-free survival (PFS) was primary. Among 267 registered patients (2009-2018), 247 were evaluable. Seventy-eight underwent resection only; their 5-year EFS/PFS was 79.5%. Six of 18 patients who relapsed after surgical resection re-entered the CVP arm. In CVP-cohort-1, 51/82 (62%) achieved a complete metabolic response (CMR). 5-year EFS was 56.4%, while 5-year PFS in the CMR group was 91.3%. In contrast, PFS in 84 CVP-cohort-2 patients was 64.7%. During CVP, 68.3% of patients experienced grade 3-4 neutropenia. No treatment-related deaths were reported. Excellent outcomes were achieved after complete resection and with low-intensive, anthracycline-free chemotherapy if 18F-FDG-PET showed CMR after chemotherapy. This strategy now constitutes the EuroNet-PHL standard of care for early-stage nLPHL. The trial was registered under EudraCT-No.: 2007-004092-19.
- 3 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (17) , 5865-5873
Open AccessEuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma
Children and adolescents with early-stage nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) have a 5-year event-free survival (EFS) of about 77% after complete lymph node resection and around 89% with anthracycline-containing chemotherapy. We investigated whether patients with early-stage nLPHL can be successfully treated with surgical resection alone or with low-intensity, anthracycline-free CVP chemotherapy for those with unresectable nodal disease. EuroNet-PHL-LP1 was a prospective phase III trial enrolling patients under 18 years with stage IA/IIA nLPHL. Completely resected lymph nodes led to active surveillance. Patients with unresectable disease received three cycles of CVP (cyclophosphamide, vinblastine, prednisone). In CVP-cohort-1, treatment cessation required a negative 18F -FDG-PET. An amendment in 2014 omitted PET for end-of-treatment response; CT and/or MRI alone defined response in CVP-cohort-2. The primary endpoint was 5-year EFS, with death, relapse, second malignancy and PET-positivity counting as events; for CVP-cohort-2, progression-free survival (PFS) was primary. Among 267 registered patients (2009-2018), 247 were evaluable. Seventy-eight underwent resection only; their 5-year EFS/PFS was 79.5%. Six of 18 patients who relapsed after surgical resection re-entered the CVP arm. In CVP-cohort-1, 51/82 (62%) achieved a complete metabolic response (CMR). 5-year EFS was 56.4%, while 5-year PFS in the CMR group was 91.3%. In contrast, PFS in 84 CVP-cohort-2 patients was 64.7%. During CVP, 68.3% of patients experienced grade 3-4 neutropenia. No treatment-related deaths were reported. Excellent outcomes were achieved after complete resection and with low-intensive, anthracycline-free chemotherapy if 18F-FDG-PET showed CMR after chemotherapy. This strategy now constitutes the EuroNet-PHL standard of care for early-stage nLPHL. The trial was registered under EudraCT-No.: 2007-004092-19.
- 30 January 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Imaging pitfalls in pediatric, adolescent, and young adult Hodgkin lymphoma: a SEARCH for CAYAHL initiative to bridge multidisciplinary patient care
Pediatric Hodgkin lymphoma (pHL) is a highly curable malignancy in children, adolescents, and young adults, and current treatment strategies aim to minimize adverse late effects. Many patients are enrolled in clinical trials with centralized review for both initial and interim staging. Although academic guidelines provide a structured framework for image interpretation, real-world clinical scenarios sometimes present imaging pitfalls that require nuanced judgment. Morphological and metabolic imaging pitfalls refer to misinterpretation of findings that occur during staging, disease evaluation, or post-treatment surveillance. In pHL, such pitfalls may result from suboptimal imaging conditions, concurrent inflammatory, infectious, or other findings. These findings do not indicate neoplastic disease but rather are manifestations of other processes specific to each tissue or organ. This Staging, Evaluation, and Response Criteria Harmonization for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL) initiative represents a transatlantic collaboration among multidisciplinary professionals, aiming to disseminate the insights gained from decades of centralized review experience in North American and European clinical trials. This article aims to optimize patient care by integrating imaging and clinical expertise in disease staging and surveillance. Although not intended as a comprehensive staging guide, it highlights recurrent imaging pitfalls that may lead to incorrect staging or response assessment. By encouraging interdisciplinary exchange, this work seeks to complement existing literature and serve as a troubleshooting guide for situations where clinical realities diverge from academic paradigms.
- 30 January 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Imaging pitfalls in pediatric, adolescent, and young adult Hodgkin lymphoma: a SEARCH for CAYAHL initiative to bridge multidisciplinary patient care
Pediatric Hodgkin lymphoma (pHL) is a highly curable malignancy in children, adolescents, and young adults, and current treatment strategies aim to minimize adverse late effects. Many patients are enrolled in clinical trials with centralized review for both initial and interim staging. Although academic guidelines provide a structured framework for image interpretation, real-world clinical scenarios sometimes present imaging pitfalls that require nuanced judgment. Morphological and metabolic imaging pitfalls refer to misinterpretation of findings that occur during staging, disease evaluation, or post-treatment surveillance. In pHL, such pitfalls may result from suboptimal imaging conditions, concurrent inflammatory, infectious, or other findings. These findings do not indicate neoplastic disease but rather are manifestations of other processes specific to each tissue or organ. This Staging, Evaluation, and Response Criteria Harmonization for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL) initiative represents a transatlantic collaboration among multidisciplinary professionals, aiming to disseminate the insights gained from decades of centralized review experience in North American and European clinical trials. This article aims to optimize patient care by integrating imaging and clinical expertise in disease staging and surveillance. Although not intended as a comprehensive staging guide, it highlights recurrent imaging pitfalls that may lead to incorrect staging or response assessment. By encouraging interdisciplinary exchange, this work seeks to complement existing literature and serve as a troubleshooting guide for situations where clinical realities diverge from academic paradigms.
- 1 January 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 314 (1) , e232650
CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL)
An international consensus definition of lymph node involvement at CT, MRI, and fluorodeoxyglucose PET/CT in pediatric Hodgkin lymphoma allows more robust comparisons between clinical trials, particularly those that include involved node or involved site radiation therapy.
- 1 January 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 314 (1) , e232650
CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL)
An international consensus definition of lymph node involvement at CT, MRI, and fluorodeoxyglucose PET/CT in pediatric Hodgkin lymphoma allows more robust comparisons between clinical trials, particularly those that include involved node or involved site radiation therapy.
- Open Access
- 1 December 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 244, 107964
Development and evaluation of a software system for medical students to teach and practice anamnestic interviews with virtual patient avatars
- 1 December 2023
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 244, 107964
Open AccessDevelopment and evaluation of a software system for medical students to teach and practice anamnestic interviews with virtual patient avatars